Headquartered in Raleigh, NC Fiscal year ends December NASDAQ: ACT enactmi.com
Enact Holdings, Inc. (Nasdaq: ACT) is a U.S. private mortgage insurance provider. It operates principally through its wholly owned subsidiary Enact Mortgage Insurance Corporation (EMICO), which has been in business since 1980.
The company partners with mortgage lenders to insure low-down-payment residential loans, mainly purchase originations. It earns premiums on that business, predominantly monthly-pay policies, and investment income on a fixed-income portfolio of roughly $5.9 billion.
As of September 30, 2026, it had about $275 billion of primary insurance in-force across roughly 934,000 policies, and about $72 billion of risk in-force.
Enact manages credit and capital risk through two main tools:
- Credit risk transfer programs, including insurance-linked notes, excess-of-loss and quota share reinsurance.
- Capital held to meet the GSEs' Private Mortgage Insurer Eligibility Requirements (PMIERs).
The company also pursues premium growth in adjacent businesses. Its results are tied to housing market activity, mortgage rates, borrower credit performance and GSE policy. Updated
Management is answering a credit wobble with cash: full-year capital return guidance now sits at roughly $600 million even as the loss ratio jumped to 20% from 14% last quarter, missing expectations.
A lender, a mortgage insurer, a Pennsylvania bank, and a Montana utility all pay dividends that earnings cover. But one of them just cut its payout, and its price tag tells you…
A new ETF that includes only U.S. firms operating in the legal cannabis market made its first appearance on Wednesday.
Many investors are focused on getting the jump on the cannabis industry, but they aren’t alone. With this increased speculation, there is added risk that has to be considered.
The ETF universe includes a variety of funds that allow investors to share in the spoils of legal gambling, smoking (tobacco and marijuana), and beer and spirits consumption. Investing in sin can…
With evolving societal and regulatory landscapes, the upside potential of cannabis as a new investment strategy has emerged. Investors can use a number of ETFs to invest in the future of cannabis.
Allergan has issued a press release that confirms some of the rumors floating in the market that it has been approached by Pfizer.
S&P Capital IQ released a report regarding the performance of companies in terms of earnings and revenue.
American Airlines will be the newest addition to the S&P 500, taking the place of Allergan.
All indexes rebalance on a quarterly basis. 24/7 Wall St. screened a recent Jefferies report for the stocks that will see the most trading on Friday's rebalance.
Salix Pharmaceuticals and Valeant Pharmaceuticals have announced that they had entered into an agreement on their plan to merge based on a new price for Salix shares.
A new report from UBS shows some serious changes made to the firm's Equity Focus list for March.
Actavis launched second-largest ever bond sale Monday to raise $21 billion to pay for its acquisition of Allergan.
The UBS CIO Wealth Management team makes a good case that investors should consider the stocks in the firm's Quality Growth at a Reasonable Price (Q-GARP) portfolio.
24/7 Wall St. has compiled a list health care stocks that Merrill Lynch expects to be top performers in 2015.
Here is a look at the top performers for 2014, nine stocks that have doubled and have a current market cap of at least $5 billion.
Enact Holdings, Inc. (Nasdaq: ACT) is a U.S. private mortgage insurance provider. It operates principally through its wholly owned subsidiary Enact Mortgage Insurance Corporation (EMICO), which has been in business since 1980.
24/7 Wall St.'s 12-month price target for ACT is $55.39, rated Buy. The Wall Street consensus target is $47.20. ACT price prediction →
